Skip to content

Shop BLIS Probiotics >

  • Solutions

    Probiotic Portfolio

    BLIS K12™

    BLIS M18™

    BLIS Q24™

    Health Areas

    ENT Health

    Immune Health

    Dental Health

    Skin Health

    Finished Goods

    BLIS Q24™ Live Probiotic Serum

    BLIS K12™ Throat Health Lozenge

    BLIS K12™ Immunity Lozenge

    BLIS K12™ Immunity Kids Powder

    BLIS K12™ Fresh Breath Lozenge

    BLIS M18™ Teeth & Gums Lozenge

  • Work With Us

    Private Label

    Ingredients

    R&D and Formulations

  • Research

    Clinical Studies

    Scientific Collaboration

  • Investor Centre

    NZX Announcements

    Annual & Half Year Reports

    Corporate Governance

    Charters & Policies

    FAQs

    Key Dates

    Investor Enquiries

  • Company

    Our Mission

    Our Story

    Facilities

    Partners

  • Knowledge

    Press

    Awards

    White Papers

    Events

CONTACT US
CONTACT US

OUR STORY

At BLIS Technologies Limited, we are committed to using the latest scientific research to develop the highest quality probiotic solutions. Our innovative products are trusted by people around the world to help them lead healthier and happier lives.

BLIS Science Lab
John Tagg founding story

FOUNDING STORY

Our company was founded by Professor Emeritus John Tagg, who was inspired to research and innovate after his early encounter with Streptococcus pyogenes – the bacteria that causes strep throat. As a child, he suffered from a series of strep sore throats that eventually led to rheumatic fever, and he had to take penicillin tablets daily for a decade to prevent further attacks.

Despite this experience, Professor Tagg was determined to find a more effective way to defend against strep throat. He wanted to prevent the illness from occurring in the first place, rather than simply treating it with antibiotics.

PROBIOTIC BREAKTHROUGH

During his research at Otago University in Dunedin NZ, Professor Tagg made a significant discovery. He found that BLIS K12™, a naturally occurring strain of Streptococcus salivarius, had the ability to prevent strep throat by stopping the growth of Streptococcus pyogenes. This breakthrough not only marked a milestone in Professor Tagg’s career, but also became the foundation for our company.

Oral Probiotic breakthrough

OUR STORY SO FAR..

A timeline of Blis Technologies Limited

Living in Melbourne, 12 year old John Tagg has a nasty encounter with Streptococcus pyogenes, the bacteria that cause strep throat. This infection leads to the development of rheumatic fever, with John then needing to take penicillin daily for the rest of his teenage years to prevent any further attacks.

1960

Living in Melbourne, 12 year old John Tagg has a nasty encounter with Streptococcus pyogenes, the bacteria that cause strep throat. This infection leads to the development of rheumatic fever, with John then needing to take penicillin daily for the rest of his teenage years to prevent any further attacks.

While studying microbiology at Melbourne University, John is inspired by Dr. Rose Mushin's teachings on bacterial interference as a natural and targeted way of preventing infections. This leads him to pursue a PhD at Monash University, where he studies the connection between S. pyogenes infections and the autoimmune symptoms of rheumatic fever.

1966

While studying microbiology at Melbourne University, John is inspired by Dr. Rose Mushin's teachings on bacterial interference as a natural and targeted way of preventing infections. This leads him to pursue a PhD at Monash University, where he studies the connection between S. pyogenes infections and the autoimmune symptoms of rheumatic fever.

John begins working at the University of Otago microbiology department where he develops a procedure for the bacteriocin 'fingerprinting' of streptococci. Through this work, he makes the exciting discovery that most streptococci appear capable of producing some type of bacteriocin-like inhibitory activity.

1975

John begins working at the University of Otago microbiology department where he develops a procedure for the bacteriocin 'fingerprinting' of streptococci. Through this work, he makes the exciting discovery that most streptococci appear capable of producing some type of bacteriocin-like inhibitory activity.

Now a Microbiology Professor, John leaves his academic position at the University of Otago to focus on the commercial development of the BLIS K12 probiotic strain that he had discovered. Blis Technologies Limited is born.

2000

Now a Microbiology Professor, John leaves his academic position at the University of Otago to focus on the commercial development of the BLIS K12 probiotic strain that he had discovered. Blis Technologies Limited is born.

Blis Technologies (BLT.NZ) is listed on the NZX Stock Exchange.

2001

Blis Technologies (BLT.NZ) is listed on the NZX Stock Exchange.

BLIS launches its first product - BLIS K12™ ThroatGuard Pro - and the world's first probiotic for oral health.

2002

BLIS launches its first product - BLIS K12™ ThroatGuard Pro - and the world's first probiotic for oral health.

Following the discovery that BLIS K12™ also inhibits the bacteria associated with bad breath, the FreshBreath kit is launched.

2002

Following the discovery that BLIS K12™ also inhibits the bacteria associated with bad breath, the FreshBreath kit is launched.

BLIS wins the 2010 Frost & Sullivan Award for Global Entrepreneurship.

2010

BLIS wins the 2010 Frost & Sullivan Award for Global Entrepreneurship.

The BLIS M18™ (Streptococcis salivarius) strain launches into the market under the brand name HealthyTeeth. Several clinical trials found BLIS M18™ to promote the health of the oral cavity.

2016

The BLIS M18™ (Streptococcis salivarius) strain launches into the market under the brand name HealthyTeeth. Several clinical trials found BLIS M18™ to promote the health of the oral cavity.

BLIS is acknowledged by multinational Deloitte as the Fastest Growing Mature Business in New Zealand for 2016.

2016

BLIS is acknowledged by multinational Deloitte as the Fastest Growing Mature Business in New Zealand for 2016.

BLIS releases a new product, this time combining both oral and gut probiotics - ULTRABlis.

2020

BLIS releases a new product, this time combining both oral and gut probiotics - ULTRABlis.

A new strain, this time for skin health - BLIS Q24™ - is released to market within the skincare product - the Live Probiotic Hydration Serum. It is the first skincare product enriched with a live skin probiotic.

2021

A new strain, this time for skin health - BLIS Q24™ - is released to market within the skincare product - the Live Probiotic Hydration Serum. It is the first skincare product enriched with a live skin probiotic.

Global probiotic company Probi acquires Blis shares and enters into a strategic partnership.

2021

Global probiotic company Probi acquires Blis shares and enters into a strategic partnership.

BLIS becomes the first Green Lab certified in New Zealand. My Green Lab’s Certification is considered the global standard for laboratory sustainability best practices around the world.

2022

BLIS becomes the first Green Lab certified in New Zealand. My Green Lab’s Certification is considered the global standard for laboratory sustainability best practices around the world.

The BLIS Q24™ Live Probiotic Hydration Serum wins the Callaghan Innovation Award at the NZ Natural Health Awards.

2022

The BLIS Q24™ Live Probiotic Hydration Serum wins the Callaghan Innovation Award at the NZ Natural Health Awards.

Solutions

  • Probiotic Portfolio
  • Health Areas
  • Finished Goods

WORK WITH US

  • Ingredients
  • Private Label
  • R&D and Formulations

Other Links

  • Investor Centre
  • Privacy Policy
  • Terms & Conditions
  • Terms of Trade

Connect With Us

  • @blis-technologies-limited
    @blis-technologies-limited
  • Info@blis.co.nz
    Info@blis.co.nz
  • Buy BLIS Probiotics Online:
BlisProbiotics.co.NZ

© 2023 Blis Technologies ·
Website crafted by Drive Digital